Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Genomics technologies revolutionised biomedicine research, but the genome alone is not sufficient to capture biological complexity. Postgenomic methods, typically based on mass spectrometry, comprise the analysis of metabolites, lipids, and proteins and are an essential complement to genomics and transcriptomics. Multidimensional omics is becoming established to provide accurate and comprehensive state descriptions. This book covers the latest methodological developments for, and applications of integrative multi-omics in biomedical research.

target identification --- target validation --- label-free method for drugs --- anti-angiogenesis --- mechanism of action --- receptor tyrosine kinases --- curcumin --- natural products --- lipid --- lipidomics --- cardiac metaplasia --- Barrett’s esophagus --- esophageal adenocarcinoma --- microbiota --- DNA sensing --- IFI16 --- cGAS --- innate immunity --- protein interactions --- virus–host interactions --- post-translational modifications --- mass spectrometry --- proteomics --- transcriptomics --- multi-omics --- multi-omics analysis --- study design --- bioinformatics --- machine learning --- analysis flow --- metabolomics --- planned myocardial infarction (PMI) --- myocardial infarction (MI) --- exercise --- heart --- cheminformatics --- batch variations --- eicosanoids --- fetal calf serum --- peroxisomes --- host-pathogen interactions --- secretome --- macrophages --- acute myeloid leukemia --- HL-60 cell line --- ATRA --- induced differentiation --- transcriptome --- proteome --- transcription factors --- key molecules --- regulatory pathway modelling --- SRM --- endometriosis --- inflammation --- n/a --- Barrett's esophagus --- virus-host interactions

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Marine herbal medicine generally refers to the use of marine plants as original materials to develop crude drugs, or for other medical purposes. The term ‘marine plants’ usually denotes macroalgae grown between intertidal and subintertidal zones, including Chlorophyta, Phaeophyta, and Rhodophyta. Considerable progress has been made in the field of biomedical research into marine microalgae and microorganisms in the past decade. As the most important source of fundamental products in the world, marine plants have a very important role in biomedical research. Furthermore, worldwide studies have consistently demonstrated that many crude drugs derived from marine plants contain novel ingredients that may benefit health or can be used in the treatment of diseases; some have been developed into health foods, and some even into drugs. It is expected that there are many substances of marine plant origin that will have medical applications in terms of improving human health and are awaiting discovery.In this Special Issue, entitled “Development and Application of Herbal Medicine of Marine Origin”, we will provide a platform for researchers to publish biomedical studies on substances of marine plant origin. We welcome submissions from scientists and academics from across the world.

marine functional foods --- vascular endothelial growth factor receptor-3 --- ultrafiltration --- lung fibrosis --- metabolic instability --- peptide fractions --- cembrane --- 3T3 fibroblasts --- Pinnigorgia sp. --- lymphatic endothelial cells --- bile salts --- caspase-3 --- cytokine --- hepatic stellate cells --- macrophage --- oral squamous cell carcinoma --- anti-inflammation --- MAPK --- fucoidan --- Jaspine B --- ACE-inhibition --- bioactivity --- sulfated galactan --- bioavailability --- ROS --- anti-angiogenesis --- briarellin --- neolignan --- radiation pneumonitis --- Pachyclavularia --- Lumnitzera racemosa --- apoptosis --- phomaketide A --- prodigiosin --- neutrophil --- intestinal permeability --- autophage --- secosterol --- octocoral --- amino acids composition --- phlorotannins --- cardiovascular-health --- antioxidant properties --- marine viva --- green seaweed --- protein enzymatic hydrolysate --- lymphangiogenesis --- edible brown algae --- briarane --- Herbs --- Marine pharmacology. --- Marine algae --- Therapeutic use. --- Sea vegetables --- Seaweed --- Seaweeds --- Vegetables, Sea --- Algae --- Marine plants --- Drugs from the sea --- Marine pharmacognosy --- Materia medica, Marine --- Marine biology --- Materia medica --- Pharmacognosy --- Herb remedies --- Herbal medicine --- Medicinal herbs

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies

Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies

Research & information: general --- Chemistry --- interleukin 33 --- ST2 receptor --- scFv --- C2_2E12 --- bladder cancer --- antibodies --- immune checkpoint inhibitors --- antibody-drug conjugates --- sacituzumab govitecan --- enfortumab vedotin --- erdafitinib --- cost-effectiveness --- G protein-coupled receptor --- membrane protein --- antigen --- therapeutic antibody --- anti-angiogenesis --- delta-like ligand --- irinotecan --- paclitaxel --- VEGF --- SARS-CoV-2 --- spike protein --- receptor-binding domain --- phage display --- monoclonal antibody --- cytomegalovirus --- peptide/major histocompatibility complex class I complex --- T-cell-receptor-like antibody --- affinity maturation --- yeast surface display --- combinatorial antibody library --- agonist antibody --- cell fate --- bispecific antibodies --- bioassays --- mechanisms of action --- binding assays --- potency assays --- atherosclerosis --- inflammation --- antibody therapy --- blood–brain barrier --- antibody --- pharmacokinetics --- disposition --- biochemical and physicochemical properties --- Fc binding --- receptor-mediated transcytosis --- brain shuttle --- molecular Trojan horse --- transferrin --- anti-cancer antibody --- antibody engineering --- biophysical properties --- computational methods --- research cell bank --- antibody therapeutics --- recombinant antibodies --- intracellular antibodies --- single-chain antibody fragment --- nanobody --- Human papillomaviruses --- HPV oncoproteins --- HPV-associated cancer --- HPV cancer therapy --- asthma --- refractory asthma --- biomarker --- n/a --- blood-brain barrier

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is a compilation of articles that brings together current knowledge from an international team of contributors who are dedicated investigators exploring novel strategies for the treatment of glioblastoma. These articles describe some of the latest concepts that will provide students, researchers and clinicians with an overview of the therapeutic approaches being developed in the field of neuro-oncology to combat this deadly disease.

Medicine --- glioblastoma --- glioma --- temozolomide --- radiotherapy --- immunotherapy --- novel therapy --- personalized treatment --- drug repurposing --- invasion --- invadopodia --- ion channels --- gene therapy --- viral vectors --- brain tumor --- nanomedicine --- cancer stem cell --- targeted therapy --- brain cancer --- cell cycle --- differentiation --- proliferation --- RAS --- SRGAP2 --- stem cell --- TP53 --- glioblastoma multiforme --- GBM --- nerve/glial antigen 2 --- NG2 --- CK2 --- CX-4945 --- migration --- CRISPR/Cas9 --- anticancer --- anti-angiogenesis --- thyrointegrin αvβ3 --- PEG --- triazole tetrac --- P-bi-TAT --- P-m-TAT --- tetrac --- one-carbon metabolism --- de novo purine synthesis --- metabolic reprogramming --- metabolic treatment --- vaccine --- immune checkpoint inhibitors --- chimeric antigen receptor (CAR) T cells --- glioblastoma (GB) --- prolyl-oligopeptidase (POP) --- vascular endothelial growth factor (VEGF) --- transforming growth factor-β (TGF-β) --- angiopoietin (Ang) --- endothelial nitric oxide synthase (eNOS) --- newly diagnosed glioblastoma --- recurrent glioblastoma --- new trial design --- drug-inducible gene expression --- Mardepodect --- Regorafenib --- drug targets --- tumor antigens --- renin–angiotensin system --- pluripotent stem cells --- organoids --- cancer stem cells --- cancer stem cell niche --- tumor microenvironment --- n/a --- renin-angiotensin system